Merck gets FDA nod for Keytruda to treat BCG-unresponsive, high-risk NMIBC

This article was originally published here

Keytruda has been approved to treat patients with BCG- unresponsive, high-risk NMIBC with carcinoma in situ (CIS) with or without papillary tumours who are ineligible for or have

The post Merck gets FDA nod for Keytruda to treat BCG-unresponsive, high-risk NMIBC appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply